Kornimate/medical-research-clean huggingface dataset:
effectiveness of vestaid app

Conditions: MTBI - Mild Traumatic Brain Injury; Vestibular Disease; Balance Deficits; Vestibular Disorders; Dizziness

Summary: this multi-center randomized trial (mcrt) will investigate the effectiveness of the vestaid application to provide equivalent or faster recovery from dizziness compared to standard-of-care delivery of vestibular rehabilitation exercises.


Eligibility criteria:
inclusion: * snellen visual acuity (corrected) greater than 20/40 * no more than 25db hearing loss at 500,1000, 2000, and 4000 hz * ability to detect 4.31 using semmes-weinstein monofilament at the lower extremity * at least 40 degrees of neck yaw motion with only mild to moderate pain (6 or under on 0-10 numeric pain scale) * internet access at home * no significant residual from past musculoskeletal or neuromuscular conditions * ability ambulates unassisted * diagnosed with a concussion or inner ear problem the last 30 days * between 18-60 years of age * can read and understand english * has complaints of dizziness exclusion criteria: * greater then 30 days since diagnosis of concussion/mtbi or inner ear problem * no access to internet at home * younger than 18 years of age or older than 60 years of age * cannot read or understand english * no complaints of dizziness and/or balance deficits * have significant neuropathy * cannot see tablet clearly at 1 meter * neck pain \&gt;5 on a 10-point pain scale.

Keywords: mtbi vestibular rehabilitation vestibular disorder technology application dizziness balance disorder image processing eye gaze compliance vor
comparative study between duct to mucosa and invagination pancreaticojejunostomy after pancreaticoduodenectomy:

Conditions: Pancreatic Anastomotic Leak

Summary: postoperative pancreatic fistula (popf) remains a challenge even at specialized centers, and also affect significantly the surgical outcomes . the incidence of popf after pancreaticoduodenectomy among different studies, ranging from 5 to 30%.morbidity and mortality after pancreaticoduodenectomy are usually related to surgical management of the pancreatic stump. the safe pancreatic reconstruction after pancreaticoduodenectomy continues to be a challenge at high volume centers. the variety of reconstruction is a reflection of the lack of ideal one.duct to mucosa and invagination are two classic pj techniques. many studies compared both techniques, but their surgical outcomes still unclear.the aim of the study was to assess the effectiveness and surgical outcomes of both techniques of pj after pancreaticoduodenectomy.

consecutive patients who were treated by pancreaticoduodenectomy at gastroenterology surgical center, mansoura, egypt exclusion criteria included any patients with locally advanced periampullary tumour, metastases, patients received neoadjuvant chemoradiotherapy, patients underwent pancreaticogastrostomy (pg), patients with advanced liver cirrhosis (child b or c), malnutrition, or coagulopathy. all patients were subjected to careful history taking, clinical examination, routine laboratory investigation abdominal ultrasound, magnetic resonance cholangiopancreatography , and abdominal computerized tomography . the patients were randomized into two groups: group i: patients underwent duct to mucosa pj. group ii: patients underwent invagination pj. the primary outcome was popf rate.secondary outcomes were operative time, operative time needed for reconstruction, length of postoperative hospital stay, postoperative morbidities

Eligibility criteria:
inclusion criteria: -consecutive patients who were treated by pancreaticoduodenectomy exclusion criteria: * any patients with locally advanced periampullary tumour, metastases * patients received neoadjuvant chemoradiotherapy * patients underwent pancreaticogastrostomy (pg) * patients with advanced liver cirrhosis (child b or c) * malnutrition * coagulopathy

Keywords: pancreaticoduodenectomy, pancreatic fistula
evaluation of bacillus clausii in treatment of acute diarrhea in latin american children

Conditions: Acute Gastroenteritis

Summary: primary objective: to demonstrate the effectiveness of treatment with bacillus clausii probiotic strain (enterogermina) in combination with oral rehydration therapy (ort) for a period of 5 days, in the duration of acute community-acquired diarrhea in latin american children. secondary objectives: to evaluate the clinical safety of enterogermina in acute diarrhea in children and to demonstrate its effectiveness on stool frequency, stool consistency, and number of vomiting episodes. to evaluate parent's overall global assessment. to evaluate the safety and effectiveness of enterogermina in norovirus acute gastroenteritis (age).

the maximum duration of study participation for each patient can be 10 days.

Eligibility criteria:
inclusion criteria: infants or children with acute community-acquired diarrhea (≥3 liquid or watery stools occurring in a 24-hour period): * with less than 48 hours duration * aged between 6 months and 5 years of age * whose parents or legal guardians have given their written informed consent * with clinical indication for ort per formula of world health organization exclusion criteria: infants or children with: * presence of blood, pus, or mucus in stools * severe dehydration * untreatable vomiting * antibiotics indication for the treatment of this acute diarrhea; * hospitalization * expected hospitalization for the next hours due to the poor clinical conditions * treatment with antibiotics, probiotics, or prebiotics within a period of 2 weeks before enrolment (the use of probiotics and prebiotics in dairy food such as yoghurt, cheese, milk prior to the study is permitted) * previous use (within 48 hours) of kaolin, pectin, bismuth subsalicylate, racecadotril, loperamide, atropine and other anticholinergic agents * indication of any other ort different from the one prescribed in the study * chronic diseases including chronic diarrhea * immunodeficiency (acquired or congenital immunodeficiency) * other infectious comorbid conditions * known hypersensitivity to bacillus clausii (enterogermina) or other probiotics * parent/legal guardian who, in the opinion of the investigator, is unable to complete the patient diary or bring the child for the follow-up visit * participation in another clinical trial in the last 3 months prior to the start of the study. the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
effect of statins on igg, iga and igm level in chronic hemodialysis patients

Conditions: Chronic Kidney Disease

Summary: this is double blind randomized controlled trial on the statins effects on serum igg, iga and igm level in chronic hemodialysis patients in bandarabbas

this study is a randomized controlled trial of statins effect on serum igg, iga and igm level on chronic hemodialysis patients in bandarabbas. the study is carried out in hormozgan, iran. seventy four patient were randomized either to receive atorvastatin in addition of usual treatment or not. the primary outcomes were serum igg,iga and igm level. the secondary outcome was drug side effects.

Eligibility criteria:
inclusion criteria: * all chronic hemodialysis patients attending shahid mohammadi hospital during the study period * accepting to participate in the study exclusion criteria: * refusing to participate in the study

Keywords: statin
a study of eli-002 in subjects with kras mutated pancreatic ductal adenocarcinoma (pdac) and other solid tumors

Conditions: Minimal Residual Disease; KRAS G12D; KRAS G12R; NRAS G12D; NRAS G12R; Pancreatic Ductal Adenocarcinoma; Colorectal Cancer; Non-small Cell Lung Cancer; Ovarian Cancer; Cholangiocarcinoma; Bile Duct Cancer; Gallbladder Carcinoma

Summary: this is a phase 1 study to assess the safety and efficacy of eli-002 immunotherapy (a lipid-conjugated immune-stimulatory oligonucleotide \[amph-cpg-7909\] plus a mixture of lipid-conjugated peptide-based antigens \[amph-peptides\]) as adjuvant treatment of minimal residual disease (mrd) in subjects with kras/neuroblastoma ras viral oncogene homolog (nras) mutated pdac or other solid tumors.

this is a phase 1 dose escalation study in which eli-002 2p (amph modified kras peptides, amph-g12d and amph-g12r admixed with admixed amph-cpg-7909) will be evaluated, with plans to transition to the eli-002 7p drug product containing all 7 amph-peptides (g12d, g12r, g12v, g12a, g12c, g12s, g13d) in future clinical trials. the study is an open-label, dose-escalation, 3+3 design in which approximately 18 subjects will be treated in 3 planned dose level cohorts. increasing doses of amph-cpg-7909 will be evaluated sequentially. additional cohorts may be added to explore intermediate or higher dose levels based on cumulative safety review and preliminary review of pharmacodynamic responses. safety and pharmacodynamic data will be evaluated and a recommended phase 2 dose (rp2d) will be determined in consideration of a maximum tolerated dose (mtd) if observed.

Eligibility criteria:
inclusion criteria: * kras/nras mutated (g12d or g12r) solid tumor * positive for circulating tumor dna (ctdna) and/or elevated serum tumor biomarker despite prior standard therapy including surgery and chemotherapy/radiation therapy where applicable * screening ct is negative for recurrent disease * eastern cooperative oncology group (ecog) performance status of 0 or 1 exclusion criteria: * presence of tumor mutations where specific therapy is approved, and the patient is able to receive the approved therapy * known brain metastases * use of immunosuppressive drugs

Keywords: minimal residual disease (mrd) kirsten rat sarcoma (kras) neuroblastoma ras viral oncogene homolog (nras) pancreatic ductal adenocarcinoma (pdac) colorectal cancer (crc) colon cancer rectal cancer non-small-cell lung cancer (nsclc) mucinous ovarian cancer cholangiocarcinoma (cca) bile duct cancer gallbladder carcinoma immunotherapy vaccine therapy adjuvant therapy circulating tumor dna (ctdna)
emerging from the haze™- measuring the impact of a psycho-education program on perceived cognition after breast cancer treatment

Conditions: Cognition; Cancer

Summary: at cedars-sinai medical center, we have developed a novel curriculum for a 6-week psycho-educationally-based, cognitive behavioral program to help patients with subjective cognitive complaints after cancer treatment, titled emerging from the haze™ (haze). each series meets once a week for 2 hours for 6 weeks. the leading neuropsychologist covers material such as guided relaxation, behavioral strategies for automatic/negative thoughts, compensatory strategies for attention and memory, executive functioning, pacing, and balance. each haze series will be electronically delivered in a live format to our satellite site, the university of kansas.


Eligibility criteria:
inclusion criteria: * completed treatment for stage 1-3 breast cancer at least two months but not more than 24 months prior to enrollment. * having received chemotherapy with or without radiation therapy * female, age ≥18 years. * fact-cog score less than 59 on the perceived cognitive impairment subscale * eligible after 2 months of completing all their active cancer treatment with the exception of long-term hormonal treatments or trastuzumab. * subjective complaint of cognitive concerns at time of enrollment * must be able to understand and communicate proficiently in english * ability to understand and the willingness to sign a written informed consent. * agree to complete study surveys exclusion criteria: * patients who have significant personality disorders or unstable psychiatric disorders (including active major depression, substance abuse, psychosis or bipolar disorder) as assessed by the interviewing clinician * patients with known brain metastases, history of brain metastases or radiation to the brain. * patients with a history of stroke or other pre-existing neurological condition that may contribute to cognitive dysfunction. * non-english speakers * receiving treatment for another malignancy other than breast cancer * uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, chronic anemia, uncontrolled hypothyroidism, symptomatic congestive heart failure, unstable angina pectoris, uncontrolled cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.

Keywords: cognitive dysfunction cancer survivorship
a study of cdp870 as add-on meditation to methotrexate (mtx) in patients with rheumatoid arthritis

Conditions: Rheumatoid Arthritis

Summary: the objective of this trial is to compare the efficacy of certolizumab (czp) (cdp870) in combination with methotrexate (mtx) to mtx alone in the treatment of signs and symptoms in patients with active rheumatoid arthritis (ra) who are incomplete responders to mtx.


Eligibility criteria:
inclusion criteria: * adult-onset ra of at least 6 months but not longer than 15 years in duration as defined by the 1987 american college of rheumatology classification criteria * active ra disease as defined by at least 9 tender joints and 9 swollen joints, esr of 30 mm/hour or crp of 1.5 mg/dl * mtx (with or without folic acid) for at least 24 weeks prior to the baseline visit, the dose of mtx and route of administration must have been stable for at least 8 weeks prior to the baseline visit. the minimum stable dose of mtx allowed is 10 mg weekly. exclusion criteria: * any other inflammatory arthritis (e.g., psoriatic arthritis, ankylosing spondylitis or reactive arthritis) * secondary, non-inflammatory type of arthritis (eg, osteoarthritis, fibromyalgia) * nyha (new york heart association) class iii or iv congestive heart failure * current or history of, tuberculosis * history of chronic infection, recent serious or life-threatening infection (within 24 weeks , including herpes zoster), or any current sign or symptom that may indicate an infection (e.g., fever, cough) * high risk of infection * have received any experimental non-biological therapy, within or outside a clinical trial in the 12 weeks prior to baseline * have received previous b-cell therapy (eg. rituximab) * have received any other biological therapy for ra within 24 weeks prior to baseline visit, except for etanercept where a three month washout prior to baseline visit is acceptable * have received previous treatment with a biological therapy for ra that resulted in a severe hypersensitivity reaction or an anaphylactic reaction * failed to respond to previous treatment with an anti-tnf drug * female breast feeding, pregnant or plan to become pregnant during the trial or for 12 weeks following the last dose of study drug

Keywords: cdp870 korea cimzia
mental health and aggression in congolese ex-combatants

Conditions: Appetitive Aggression; Posttraumatic Stress Disorder

Summary: the purpose of this study is examine, whether a treatment approach, which is specifically tailored for perpetrators who have participated in violence (a variant of narrative exposure therapy) is effective in the reduction of instrumental aggression and symptoms of posttraumatic stress disorder.

the reintegration of former child soldiers and ex-combatants is a big challenge in war-torn countries. former child soldiers and ex-combatants often suffer from mental health problems and show enhanced levels of aggression. the present study focuses on the reduction of appetitive aggression and the improvement of mental health in former child soldiers and ex-combatants in dr congo.

Eligibility criteria:
inclusion criteria: * ex-combatants in congo who live in a re-integration camp

Keywords: treatment of ex-combatants narrative exposure therapy for ex-combatants appetitive aggression posttraumatic stress disorder
rosacea radiofrequency microneedling

Conditions: Rosacea, Papulopustular; Rosacea, Erythematotelangiectatic

Summary: there are 3 main objectives of this proposal as follows: (1) to assess the efficacy of radiofrequency microneedling in the treatment of erythematotelangiectatic and or papulopustular rosacea, (2) to determine the potential for combination treatment of radiofrequency microneedling with the 532 nm ktp laser, and (3) identify potential novel therapeutic strategies for the treatment of rosacea.


Eligibility criteria:
inclusion criteria: 1. male or female adult (\>18yo) subjects in general good health 2. clinical and/or histologic diagnosis of erythematotelangiectatic or papulopustular rosacea. 3. subject is able to understand and sign informed consent 4. subject is able to complete the study and comply with study procedures exclusion criteria: 1. patients currently utilizing oxymetazoline or brimonidine. 2. presence of dermatoses that might interfere with diagnosis as determined by a study investigator 3. presence of extreme light sensitivity, or conditions pre-disposing to light sensitivity such as but not limited to xeroderma pigmentosum 4. any significant medical condition that may prevent the patient from participating in the study according to the investigator's assessment 5. history of poor wound healing or blood-clotting abnormality 6. history of keloid formation or hypertrophic scarring 7. hypersensitivity or contraindication to local anesthetics as determined by the principal investigator or other medical professional. 8. prisoners
antibacterial photodynamic therapy in the management of peri-implantitis

Conditions: Peri-Implantitis; Plaque, Dental

Summary: this early-stage study is designed to determine the efficacy of the lumoral method in periimplantitis. improved supragingival plaque control can help to also sustain subgingival plaque management in the long term. in addition, the device might have a photobiomodulation effect on periodontal tissues, thus impacting osseointegration.

clinical signs of inflammation in peri-implantitis include bleeding on probing, suppuration, increased probing depth, and radiographic signs of bone loss. currently, the best treatment options for peri-implantitis include non-surgical methods of biofilm removal in the supra-mucosal area around implants, and comprehensive guidance on self-performed infection control procedures. with more advanced peri-implantitis, anti-infective surgical treatment protocol would be needed. matrix metalloproteinase 8 (mmp-8) has been found to be elevated in association with oral infections, such as periodontitis and peri-implantitis. the level of active mmp-8 (ammp-8) can detect to determine tissue health and to assess inflammation, and can easily be measured during a regular dental appointment with a chairside test. the lumoral treatment is a ce-marked medical device developed to provide a potent, targeted antibacterial action on dental plaque in a home environment. the method mechanism of action is antibacterial photodynamic therapy (apdt). the method is used by swishing a mouth rinse, which has a strong adherence to dental plaque. the plaque-adhered photoactive mouth rinse can be activated by a simple-to-use light applicator. preliminary results have shown a promising anti-inflammatory response in addition to plaque reduction.

Eligibility criteria:
inclusion criteria: * ppd ≥6 mm and marginal bone loss \>3 mm * dental implants collected and clinically characterized according to lähteenmäki et al. cedr-22 * agreement to participate in the study and to sign a written consent form * able to co-operate with the treatment protocol and avoid any other oral hygiene measures outside of the study protocol exclusion criteria: * presence of any physical limitation or restriction that might restrict lumoral use * unwilling to participate in the study * pregnancy or lactation * active smoking * medicated diabetes mellitus (dm) * any systemic disease (e.g., wound healing dysfunctions) that could alter the progression of peri-implantitis * use of antibiotics and doxycycline, chlorhexidine, and bisphosphonates, within 4 weeks week prior to study participation * peri-implant and periodontal treatment within 3 months prior to study participation * removable major prosthesis or major orthodontic appliance

Keywords: lumoral lumorinse antibacterial photodynamic therapy (abpt) ammp-8 plaque control
appendicitis and laparoscopic criteria; appel study

Conditions: Appendicitis

Summary: a diagnostic laparoscopy is frequently used to confirm the diagnosis of appendicitis. however, laparoscopic criteria for determining appendicitis are not defined. if there is any doubt about the presence of an abnormal appendix, it is usually removed. however, an appendectomy of a negative appendix has a certain morbidity and for that reason it should be avoided. the purpose of this study is to establish laparoscopic criteria for the diagnosis appendicitis during diagnostic laparoscopy.

the umcg hospital protocol of suspicion of appendicitis includes a diagnostic laparoscopy. the laparoscopic inspection of the appendix is carried out according to a specific protocol. in case of appendicitis the appendix is removed laparoscopically, a normal appendix is not removed. the primary outcome of the study is: appendicitis according to pathologic examination following appendectomy, or appendicitis according to clinical follow-up in case the appendix is not removed. the clinical diagnosis of appendicitis in the follow-up should be confirmed radiologic examination (ultrasound, ct-scan, mri) or by a re-operation.

Eligibility criteria:
inclusion criteria: * informed consent * patients who will undergo a diagnostic laparoscopy for suspicion of appendicitis * no age or gender limits exclusion criteria: * elective scheduled appendectomy * unable to give informed consent

Keywords: appendicitis laparoscopy appendectomy